Wall Street is positive on C4 Therapeutics Inc (CCCC). On average, analysts give C4 Therapeutics Inc a Buy rating. The average price target is $15.272, which means analysts expect the stock to increase by 891.69% over the next twelve months.
That average ranking earns C4 Therapeutics Inc an Analyst Rating of 33, which is better than 33% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating CCCC a Buy today. Find out what this means to you and get the rest of the rankings on CCCC!
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With C4 Therapeutics Inc Stock Today?
C4 Therapeutics Inc (CCCC) stock is trading at $1.54 as of 1:30 PM on Tuesday, Nov 21, a decline of -$0.16, or -9.17% from the previous closing price of $1.69. The stock has traded between $1.50 and $1.68 so far today. Volume today is low. So far 225,176 shares have traded compared to average volume of 556,975 shares.
Click Here to get the full Stock Report for C4 Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
